MARKSANS

Marksans Pharma Ltd.

NSE: MARKSANS

BSE: 524404

Sector: Healthcare

Industry Group: Pharmaceuticals & Biotechnology

Industry: Pharmaceuticals

335.90+0.8 (+0.25%)

8 Sep, 12:00 AM

Overview

Analysis Statements Technicals Forecast Peers Resources News

Stock Scores

Quality Score

92.2 / 100

Value Score

40.9 / 100

Price Momentum Score

97.1 / 100

QVM Score

96.1 / 100

Key Metrics

Market Cap

15221.80

P/E (TTM)

29.33

P/B

5.04

P/S (TTM)

4.80

EV/EBITDA

20.42

CAPE (5Y)

44.89

ROE (TTM)

15.22

ROCE (TTM)

16.26

ROA (TTM)

11.77

Avg 3Y ROE

16.16

Earnings 3Y CAGR

20.94

Sales 3Y CAGR

18.25

Sales 5Y CAGR

17.87

Debt/Equity

0.11

Consensus TP

294.00

Strong Buy %

Promoter Holding

43.87

Pledged %

0.00

Stock Analysis

Fundamental analysis overview of Marksans Pharma Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.

Views

Red Flags

Positive

Strong price momentum

Price Momentum score of 97.1 indicates that the stock has strong price momentum. Research has shown that stocks with higher momentum continue to outperform in the near term

What is Price Momentum score?

97.1 / 100

Analysts have been raising forward EPS estimates

Analyst EPS estimate (consensus) for forward EPS has increased by 4.49% in the last 3 months, indicating earnings momentum

What is Earnings upgrade (3M)?

High and stable operating margin

The company reported strong operating margin of 17.1% for 12-month ended 30 Jun 2026 and operating margin improved marginally by 148 bps from 1 year ago

What is Operating profit margin?

Moderate revenue growth and above median growth of industry

The company delivered moderate revenue growth of 19.59% for 12-month ended 30 Jun 2026 and the growth was 9.0 percentage points higher than median growth of industry

What is Sales growth (1Y)?

Median: 10.59

Value 19.59

-99.6111701.8

Strong EPS growth and above median growth of industry

The company delivered strong EPS growth of 47.59% for 12-month ended 30 Jun 2026 and the growth was 40.39 percentage points higher than median growth of industry

What is EPS growth (1Y)?

Low Debt to Equity, not much change from last year

The company has low Debt to Equity of 0.11 as on 30 Jun 2026 and Debt to Equity decreased marginally by 0.02 in the last 1 year

What is Debt to Equity?

Consistently pays dividend

The company has not missed dividend payments once in the last 10 financial years

What is Dividend streak?

Company is net cash

The company is net cash i.e., cash and cash equivalents exceed total debt indicating a healthy balance sheet

What is Net Debt ?

Negative

Expensive and at same valuation levels as industry median P/E

PE TTM of 29.33 indicates that the stock is expensive on a standalone basis. Discount to industry median P/E is modest at -7.71%

What is P/E Ratio?

Median: 31.78

Value 29.33

-0.96721.13

Low dividend yield

The company has a low dividend yield of 0.27%

What is Dividend yield?

Neutral

High ROE but declining trend

The company reported strong ROE of 15.22% for 12-month ended 30 Jun 2026 but ROE declined by -158 bps from 1 year ago

What is ROE (FY)?

Company's earnings are of moderate quality

Earnings quality score of 66.8 indicates that the company's earnings are of moderate quality. Earnings quality is measured using combination of earnings persistence, probability of manipulation and earnings to cash conversion

What is Earnings quality score?

66.8 / 100

Financial Snapshot

See detailed analysis

Multi-year trends for Marksans Pharma Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.

Net Revenue FY

Profit After Tax FY

ROE FY

EBITDA FY

Marksans Pharma Ltd. Shareholding Pattern

Quarterly breakdown of Marksans Pharma Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.

	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Total Promoter	48.25	48.25	48.25	48.25	48.25	48.25	48.25	48.25	48.25	48.25	48.60	49.00	43.85	43.85	43.85	43.85	43.85	43.87	43.87	43.87	43.87	43.87	43.87	43.87	43.87	43.87
Indian Promoter	48.25	48.25	48.25	48.25	48.25	48.25	48.25	48.25	48.25	48.25	48.60	49.00	43.85	43.85	43.85	43.85	43.85	43.87	43.87	43.87	43.87	43.87	43.87	43.87	43.87	43.87
Foreign Promoter	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Institutions	3.43	3.95	4.99	5.35	4.68	3.70	3.17	3.00	3.93	4.98	5.01	5.20	16.58	18.56	19.09	20.32	20.74	22.34	25.41	26.26	26.76	25.38	22.20	14.03	23.33	23.66
Mutual Funds / UTI	-	-	-	0.01	0.09	0.34	0.34	0.34	0.46	0.95	0.95	0.96	0.86	2.79	3.15	3.82	4.23	2.82	3.02	3.15	3.37	3.55	3.92	4.41	4.66	4.36
FI/Bank/Insurance	0.64	0.43	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Govt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
FII	2.54	3.28	4.69	5.05	4.34	3.14	2.64	2.59	3.46	4.04	4.06	4.23	15.11	14.90	15.07	15.55	15.57	18.59	21.31	21.95	22.19	19.89	16.92	8.13	16.76	17.47
Other Institutions	0.30	0.44	1.25	0.29	0.24	0.81	0.19	0.07	0.00	0.00	0.00	0.00	0.60	0.86	0.87	0.94	0.94	0.93	1.08	1.15	1.19	1.95	1.36	1.50	1.91	1.83
Non-Institution	48.32	47.80	46.76	46.40	47.07	48.05	48.58	48.75	47.82	46.77	46.38	45.80	39.58	37.59	37.06	35.83	35.40	33.78	30.71	29.87	29.37	30.75	33.93	42.09	32.79	32.47
Bodies Corporate	1.94	1.97	1.71	1.81	1.77	2.49	2.41	2.65	2.68	2.61	2.54	2.44	2.13	2.30	2.06	2.07	1.52	1.50	1.42	1.25	1.30	1.67	1.83	1.92	1.90	1.79
Others (incl. Retail) No. of shareholders	46.38 1,22,695	45.83 1,23,694	45.05 1,25,500	44.59 1,29,590	45.30 1,34,766	45.56 1,88,306	46.17 2,00,872	46.10 2,14,432	45.14 2,19,541	44.16 2,20,811	43.84 2,17,212	43.36 2,12,580	37.45 1,97,822	35.29 1,87,848	35.00 2,07,283	33.76 2,36,712	33.88 2,54,015	32.28 2,34,839	29.29 2,47,944	28.62 2,58,854	28.07 2,56,400	29.08 2,55,069	32.10 2,64,527	40.17 2,53,958	30.89 2,45,093	30.68 2,45,433

Holdings and Presence

Indices and prominent investors with a stake in this stock.

Index Presence

#	Index	Weight	Rank
1	Nifty Microcap 250	0.61%	40 / 250
2	Nifty Total Market	0.03%	439 / 749

Prominent Investor Holdings

Bulk, Block and Insider Trades

Recent bulk deals, block deals, and insider trading activity in Marksans Pharma Ltd. shares as reported to NSE and BSE.

Name	Month	Transaction	Holding % pre transaction	Average price	Qty.	Transaction value
Sandra Saldanha Promoter	June-2024	Market Purchase (Acquisition) 6th Jun 2024	0.06 %	₹ 141.48	63.28 k	₹ 89.52 lac
Sandra Saldanha Promoter	June-2024	Market Purchase (Acquisition) 4th Jun 2024	0.05 %	₹ 146.01	47.00 k	₹ 68.62 lac
Arvind Singh Employee	August-2023	Market Purchase (Acquisition) 22nd Aug 2023	0.00 %	₹ 115.75	3.00 k	₹ 3.47 lac
Arvind Singh Employee	August-2023	Market Sale (Disposal) 22nd Aug 2023	0.00 %	₹ 114.90	3.00 k	₹ 3.45 lac
Arvind Singh Employee	August-2023	Market Sale (Disposal) 22nd Aug 2023	0.00 %	₹ 163.92	2.00 k	₹ 3.28 lac
Arvind Singh Employee	August-2023	Market Sale (Disposal) 22nd Aug 2023	0.00 %	₹ 117.06	6.50 k	₹ 7.61 lac
Sandra Saldanha Promoter	March-2023	Market Purchase (Acquisition) 16th Mar 2023	0.02 %	₹ 66.69	1.45 lac	₹ 96.70 lac
Mark Saldanha Promoter	March-2023	Conversion of security (Acquisition) 2nd Mar 2023	43.58 %	₹ 74.00	10.00 lac	₹ 7.40 cr
Sandra Saldanha Promoter	March-2023	Market Purchase (Acquisition) 1st Mar 2023	0.00 %	₹ 67.46	75.00 k	₹ 50.60 lac

Corporate Actions

History of Marksans Pharma Ltd. dividends, bonus issues, stock splits, rights issues, and other corporate events.

Dividend₹ 0.90/share
Record date: 20th Aug 2026Ex-date: 20th Aug 2026
Announced on: 26th May 2026
Dividend₹ 0.80/share
Record date: 1st Aug 2025Ex-date: 1st Aug 2025
Announced on: 19th May 2025
Dividend₹ 0.60/share
Record date: 17th Sep 2024Ex-date: 17th Sep 2024
Announced on: 30th May 2024
Dividend₹ 0.50/share
Record date: 7th Jun 2023Ex-date: 7th Jun 2023
Announced on: 24th May 2023
Dividend₹ 0.25/share
Record date: 22nd Aug 2022Ex-date: 19th Aug 2022
Announced on: 31st May 2022

Company Profile

Overview of Marksans Pharma Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.

Marksans Pharma Limited is engaged in research, manufacture, marketing and sales of pharmaceutical formulations. It operates two manufacturing facilities in Goa and maintains two research and development centers; one located in Goa and the other in Navi Mumbai. Its focus areas lie in the over the co...

Key personnel

Mr. Jitendra Sharma

Group Chief Financial Officer

Mr. Harshavardhan Panigrahi

Company Secretary, Compliance Officer

Mr. Sathish Kumar

Managing Director - UK Operations

Mr. David Mohammed

Managing Director - Australia Operations

Mr. Anjani Kumar

Chief Operating Officer - US Operations

Mr. Mark B. SaldanhaD

Executive Chairman of the Board, Managing Director

Mr. Varddhman Vikramaditya JainD

Whole Time Director

Mrs. Sandra SaldanhaD

Whole Time Director

View all

Incorporated on

16 Apr 1992

Last Annual

31 Mar 2026

Last Interim

30 Jun 2026

No. of Employees

1,685

IPO date

03 Apr 2002

Free Float

21,52,90,856

Website

https://www.marksanspharma.com/

Phone no.

+912240012000

Address

11th Floor Grandeur,, Off Veera Desai Road, Opp Gundecha Symphony,Andheri (W), MUMBAI, 400053, India

Frequently Asked Questions

What is the current share price of Marksans Pharma Ltd.?

The current share price of Marksans Pharma Ltd. is ₹ 335.90 as of 8 Sep 2026.

What is the market capitalisation of Marksans Pharma Ltd.?

The market capitalisation of Marksans Pharma Ltd. stands at ₹ 15,221.80 Cr.

What is the PE ratio of Marksans Pharma Ltd.?

The Price-to-Earnings (PE) ratio of Marksans Pharma Ltd. is 29.33 as of the latest trailing twelve months data.

What is the ROE and ROCE of Marksans Pharma Ltd.?

Marksans Pharma Ltd. has a Return on Equity (ROE) of 15.22% and a Return on Capital Employed (ROCE) of 16.26% as per the latest financial reports.

What is the 52-week high and low of Marksans Pharma Ltd.?

The 52-week high of Marksans Pharma Ltd. is - and the 52-week low is -.

What is the dividend yield of Marksans Pharma Ltd.?

The dividend yield of Marksans Pharma Ltd. is 0.27% based on the current market price.

What is the FII and DII holding in Marksans Pharma Ltd.?

Foreign Institutional Investors (FII) hold 17.47%, Domestic Institutional Investors (DII) hold 4.36% and retail/public investors hold 30.68% of Marksans Pharma Ltd. shares.

What sector does Marksans Pharma Ltd. belong to?

Marksans Pharma Ltd. operates in the Healthcare sector.

What is the beta of Marksans Pharma Ltd.?

The beta of Marksans Pharma Ltd. is 0.98, indicating its price volatility relative to the broader market. Over the past 1 year, Marksans Pharma Ltd. has delivered an absolute return of 96.43%.

What is the RSI of Marksans Pharma Ltd.?

The 14-day Relative Strength Index (RSI) of Marksans Pharma Ltd. is 65.25, placing it approaching overbought territory. An RSI above 70 is considered overbought and below 30 is considered oversold.

Marksans Pharma Ltd.

Stock Scores

Key Metrics

Share Price

Stock Analysis

Financial Snapshot

Marksans Pharma Ltd. Shareholding Pattern

Holdings and Presence

Bulk, Block and Insider Trades

Corporate Actions

Company Profile

Frequently Asked Questions

Stock Analysis

Corporate Actions

Company Profile

Holdings and Presence